EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Management of Facial Immune Checkpoint Inhibitor-Induced Vitiligo with Topical Ruxolitinib: Quantitative Assessment Using a Semi-Automatic Tool

Thomas Breakell, Paolo Neri iD, Léonie A N Staats, Rafaela Kramer, Carola Berking iD, Michael Erdmann iD, Anke Hartmann

Current Oncology · 21.05.2026 · 33 (5) · 300

DOI: 10.3390/curroncol33050300 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Current Oncology, online erschienen am 21.05.2026. Verfasst von Thomas Breakell und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Uniklinikum Erlangen, Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erla…. Hauptthemen laut MEDLINE: Vitiligo, Pyrazoles, Nitriles, Pyrimidines. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) have substantially improved outcomes in advanced melanoma but are frequently linked to immune-related adverse events (irAEs). Vitiligo is a common cutaneous irAE and has been consistently associated with improved patient outcome, including prolonged progression-free and overall survival. It also represents significant visual stigma, particularly when the face is involved. Traditional treatment comprises topical steroids, calcineurin inhibitors, laser, and phototherapy which often have insufficient effects. Since 2023, the first approved drug for non-segmental vitiligo (NSV) with facial involvement, the topical Janus kinase inhibitor ruxolitinib, has been available. However, experience with its use in ICI-induced vitiligo remains limited. In this exploratory analysis, three patients who developed facial vitiligo following ICI therapy applied 1.5% ruxolitinib cream to affected facial areas twice daily. After six (two patients), and twelve months (one patient), extensive repigmentation was observed, quantified at 95.7%, 78.9%, and 99.1% using a novel semi-automatic tool. Quality-of-life questionnaires showed mean reductions of 57.6% (Vitiligo DLQI) and 68.2% (Vitiligo-specific Quality of Life) in disease burden. Treatment was associated with substantial repigmentation without observed side effects. Further evaluation in larger, prospective cohorts is warranted to better define treatment effects, clinical applicability, and long-term safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VitiligoPyrazolesNitrilesPyrimidinesImmune Checkpoint InhibitorsHumansFemaleMaleFaceMiddle AgedAdministration, TopicalQuality of Life

Stichwörter der Autor:innen

JAK inhibitorimmune checkpoint inhibitorimmune-related adverse eventmelanomaruxolitinibvitiligo

Substanzen

PyrazolesruxolitinibNitrilesPyrimidinesImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Dermatology, Uniklinikum Erlangen, Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
  • Comprehensive Cancer Center Erlangen-EMN and CCC Alliance WERA, 91054 Erlangen, Germany.
  • Bayerisches Zentrum für Krebsforschung (BZKF), 91052 Erlangen, Germany.
  • Department of Civil and Industrial Engineering, University of Pisa, 56122 Pisa, Italy.

ORCID-Profile: Paolo Neri, Carola Berking, Michael Erdmann

Zitieren

APA

Breakell, T., Neri, P., Staats, L. A. N., Kramer, R., Berking, C., Erdmann, M., & Hartmann, A. (2026). Management of Facial Immune Checkpoint Inhibitor-Induced Vitiligo with Topical Ruxolitinib: Quantitative Assessment Using a Semi-Automatic Tool. Current Oncology, 33(5), 300. https://doi.org/10.3390/curroncol33050300

Vancouver

Breakell T, Neri P, Staats LAN, Kramer R, Berking C, Erdmann M, et al. Management of Facial Immune Checkpoint Inhibitor-Induced Vitiligo with Topical Ruxolitinib: Quantitative Assessment Using a Semi-Automatic Tool. Current Oncology. 2026;33(5):300. doi:10.3390/curroncol33050300

BibTeX
@article{Breakell2026,
  author = {Breakell, Thomas and Neri, Paolo and Staats, Léonie A N and Kramer, Rafaela and Berking, Carola and Erdmann, Michael and Hartmann, Anke},
  title = {Management of Facial Immune Checkpoint Inhibitor-Induced Vitiligo with Topical Ruxolitinib: Quantitative Assessment Using a Semi-Automatic Tool},
  journal = {Current Oncology},
  year = {2026},
  volume = {33},
  number = {5},
  pages = {300},
  doi = {10.3390/curroncol33050300}
}
Kostenlos starten →